Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Biotechnology

Healthcare
$3.57 -3.40%

-$0.24 today

Market cap
$104.19M
Beta
1.73
P/E (TTM)
-40.8
EPS (TTM)
-$0.17
52W Low $3.71High $8.74

Volume 1.39M

Average 0.65M

UNCY Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Unicycive Therapeutics, Inc.NASDAQ: UNCY

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 239.08M shares rose 1946.6% year over year, ahead of the +1278.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 50.5% from the prior quarter. Over 3 fiscal years it compounded at +372.5% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1946.6% holds above the trailing-twelve-month pace of +1278.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
239.08M+50.5% QoQ
Last fiscal yearDec 2025
158.87M+2271.7% YoY
LTMMar 2026
107.08M+1278.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1946.6%——
1 year+2271.7%——
3-year CAGR+372.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
158.87M USD
Year-over-year change
+2271.7%
4-year CAGR
+241.5%

Weighted Avg Shares vs competitors

How UNCY compares with its peers on the latest reported figures

  • UNCY's LTM Mar 2026 weighted avg shares of 107.08M shares is the 3rd highest of the 10 companies compared; the peer median is 52.9M shares.
  • Its year-over-year change of +1278.7% is the highest of 10, against a peer median of +55.6%.
  • Over three fiscal years its annual growth of +372.5% compares with a peer median of +14.6%.
UNCY Competitors Peer median
Weighted Avg Shares for UNCY and competitors
Company Period LTM YoY 3-year CAGR
CBUSCibus, Inc.LTM Mar 2026301.04M +1164.8%-7.5%
VXRTVaxart, Inc.LTM Mar 2026232.05M +14.5%-22.1%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026107.08M +1278.7%+372.5%
BMEABiomea Fusion, Inc.LTM Mar 202656.46M +55.6%+21.3%
RLMDRelmada Therapeutics, Inc.LTM Mar 202655.31M +82.9%+10.0%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 202652.9M +2.4%+4.8%
HYFTMindWalk Holdings Corp.LTM Jan 202641.36M +43.8%+19.2%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 202638.56M +2.3%+20.7%
CAMPCAMP4 Therapeutics CorporationLTM Mar 202637.54M +102.0%—
IMUXImmunic, Inc.LTM Mar 202619.58M +98.7%+69.8%
Peer median (excluding UNCY) 52.9M+55.6%+14.6%

Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0951K675K00
Cost of Revenue0000572K
Gross Profit0951K675K0(572K)
Gross Margin—100.0%100.0%——
Research & Development6.08M12.44M12.9M20.01M9.12M
Selling, General & Admin2.9M6.57M8.55M12.1M20.4M
Operating Expenses8.98M19M21.45M32.12M28.95M
Depreciation & Amortization13K161K284K428K572K
EBITDA(9.38M)(17.89M)(30.18M)(36.23M)(25.91M)
EBITDA Margin—-1881.3%-4470.8%——
Operating Income(8.98M)(18.05M)(20.77M)(32.12M)(29.52M)
Operating Margin—-1898.2%-3077.6%——
Interest Income00615K1.26M1.01M
Interest Expense628K6K82K71K71K
Other Income / Expenses(1.04M)(6K)(9.77M)(4.61M)2.96M
Income Before Tax(10.02M)(18.06M)(30.54M)(36.73M)(26.56M)
Pre-Tax Margin—-1898.8%-4525.0%——
Income Tax Expense00000
Net Income(10.02M)(18.06M)(30.54M)(36.73M)(26.56M)
Net Margin—-1898.8%-4525.0%——
EPS (Basic)(8.60)(1.20)(1.28)(5.60)(1.67)
EPS (Diluted)(8.60)(1.20)(1.28)(5.60)(1.67)
Weighted Avg Shares1.17M1.51M2.45M6.7M158.87M
Weighted Avg Shares (Diluted)1.17M1.51M2.45M6.7M158.87M

Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Intrinsic Alpha fair value

Locked

Current Price

$3.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.